UBS O'Connor’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

UBS O'Connor’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-26,100	Closed	-$78K	–	588
2015 Q3	$78K	Buy	+26,100	New	+$825K	﹤0.01%	467

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS O'Connor's HZNP Position: Q4 2023 in Review

UBS O'Connor sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 7,664,245 shares — an estimated $887M sold.

UBS O'Connor first reported a position in HZNP in Q2 2013 and held it in 10 quarters. The position peaked at $887M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

UBS O'Connor reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
UBS O'Connor sold 7,664,245 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $887M.
UBS O'Connor first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 10 quarters.
UBS O'Connor's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $887M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.